Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are proposed as potential biomarkers to monitor the course of MS (Kuhle et al., 2016; Meier et al., 2023) and of its murine model. The gene discussed is GFAP; the disease is myeloid sarcoma.